Navigation Links
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
Date:4/21/2008

First Patient Dosed in Phase 1 Trial of SBI-087, Trubion's Next-Generation

Candidate

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing SBI-087 and other CD20-directed products. SBI-087 for RA builds on Trubion and Wyeth's clinical experience with Trubion's lead compound, TRU-015, and is based on Trubion's Small Modular ImmunoPharmaceutical (SMIP(TM)) technology.

The Phase 1 SBI-087 dose escalation clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087 in patients with RA. Preclinical research suggests that SBI-087, a fully humanized CD20-directed SMIP, has enhanced potency in B-cell depletion in vivo compared with Rituxan. This Phase 1 trial is designed to enroll patients who meet the criteria for RA with Functional Class I, II or III, and who have been diagnosed with RA more than six months prior to the study with onset of RA after the age of 16.

With SBI-087, Trubion's pipeline now includes two differentiated compounds under development for the treatment of autoimmune and inflammatory diseases: TRU-015 and SBI-087. Trubion and Wyeth are leveraging Trubion's
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/ssvbft/europe_ultrasound ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... European market is dominated by the likes of UK ... and Germany . This can ... in these regions. The European Ultrasound devices ...
(Date:6/3/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6xfc66/europe_ct_market ) has announced ... Growth, Trends And Forecasts (2014 - 2019)" report ... an imaging process that customs special x-ray equipment to ... areas inside the body. It is also called computerized ... primarily used in the Cancer diagnosis process. In addition ...
(Date:6/3/2015)... , June 3, 2015 TWi Pharmaceuticals, ... it has received final approval from the United ... Abbreviated New Drug Application (ANDA) for Guanfacine HCl ... Intuniv®.  TWI,s marketing partner, Par Pharmaceuticals, will launch ... Intuniv® is indicated for the treatment of ...
Breaking Medicine Technology:European Ultrasound Devices Market Report 2015-2019 2Europe CT Market Report 2015-2019 - Growth, Trends And Forecasts 2
(Date:6/3/2015)... 2015 evigilo, a world leader ... reported of its "behind-the-scenes" involvement in heroic, lifesaving ... Since March this year, an unusual and violent ... South-American country, putting millions in danger. , Multiple ... the atmosphere. "evigilo's technology, adopted by the Chilean ...
(Date:6/2/2015)... (PRWEB) June 03, 2015 BALTIMORE, Md. ... to write a book about wellness after being diagnosed ... she believes that through lifestyle changes which enhance health, ... In “ A Wellspring for Wellness ,” she ... diseases. , This book provides an overview of ...
(Date:6/2/2015)... The organic cotton market is again growing ... study conducted by Textile Exchange, an international nonprofit organization ... released today, encompasses extensive data about organic cotton from ... also takes the opportunity to celebrate those who are ... The last several years have been complicated for the ...
(Date:6/2/2015)... 2015 Concorde Career Colleges, Inc., announced ... COO. Bell will manage day-to-day operations for the privately ... to the opportunity to help our Concorde team deliver ... joined Concorde in part due to reports like Beyond ... colleges in Memphis and Portland.” , Bell brings 14 ...
(Date:6/2/2015)... NC (PRWEB) June 02, 2015 Food ... hosting its sixth annual “Thriller on the Griller” events, ... Carolina and South Carolina locations. Each event will raise ... dedicated to restoring a sense of self, restoring the ... and our military families. , Through these events, ...
Breaking Medicine News(10 mins):Health News:Thousands of Lives Saved, Millions Protected in Chile 2Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 2Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 4Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 5Health News:Concorde Career Colleges Announces New President and COO 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 3
... DALLAS June 3, 2009 A simple magnetic resonance ... the best treatment for some cancer patients, report researchers at ... that the amount of oxygen present in a tumor can ... to treatment. Tumors with little oxygen tend to grow stronger ...
... 2 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... ), a leading,fully integrated pharmaceutical company producing over-the-counter drugs ... it obtained,approval from the State Food and Drug Administration ... drops. The document number for the drug is,2009S02063. , ...
... , This release is available in <A ... induce cells from pigs to transform into pluripotent stem ... capable of developing into any type of cell in ... world that this has been achieved using somatic cells ...
... than 25 years of experience to support growing demand ... June 2 Covance Inc. today announced Monte Jarvis ... for periapproval services. With more than 25 years ... global data management, Jarvis will oversee data management and ...
... June 2 The National Press Club Newsmaker ... Wednesday, June 3, with Argonne National Laboratory Director ... and cannot travel to Washington. , , ... ) , , The press conference ...
... Foundation,s Annual Salute to Service Award , , ... consecutive year, Jim Kerwin of Oxford Communications ( www.oxfordcommunications.bm ... that Oxford Communications will be the primary sponsor of ... Luncheon on June 17th and Celebrity Golf Tournament to ...
Cached Medicine News:Health News:Oxygen + MRI might help determine cancer therapy success, researchers find 2Health News:China Sky One Medical, Inc. Obtains SFDA Approval for Diclofenac Sodium Eye Drops 2Health News:China Sky One Medical, Inc. Obtains SFDA Approval for Diclofenac Sodium Eye Drops 3Health News:World first: Chinese scientists create pig stem cells 2Health News:World first: Chinese scientists create pig stem cells 3Health News:Covance Announces Monte Jarvis as Vice President of Global Data Management and Biostatistics for Periapproval Services 2Health News:Covance Announces Monte Jarvis as Vice President of Global Data Management and Biostatistics for Periapproval Services 3Health News:Jim Kerwin Announces Oxford Communications To Be the Title Sponsor of Bermuda Health Foundation Salute for the Second Year 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: